SELECT Publication

(click here for full publication list)

Lab members in bold; #, co-first author; ^, co-senior author.

preprints

  • Gretarsson KH, Abini-Agbomson S, Gloor SL, Weinberg DN, McCuiston JL, Kumary V, Hickman AR, Sahu V, Lee R, Xu X, Lipieta N, Flashner S, Adeleke OA, Popova IK, Taylor HF, Noll K, Windham CL, Maryanski DN, Venters BJ, Nakagawa H, Keogh MC^, Armache KJ^, Lu C^. Cancer-associated DNA Hypermethylation of Polycomb Targets Requires DNMT3A Dual Recognition of Histone H2AK119 Ubiquitination and the Nucleosome Acidic Patch. bioRxiv 2024 [Pubmed].

  • Krug B, Hu B, Chen H, Ptack A, Chen X, Gretarsson KH, Deshmukh S, Kabir N, Faria Andrade A, Jabbour E,  Harutyunyan AS, Lee J, Hulswit M, Faury D, Russo C, Xu X, Johnston MJ, Baguette A, Dahl NA, Weil AG, Ellezam B, Dali R, Blanchette M, Wilson K, Garcia BA, Soni RK, Gallo M, Taylor MD, Kleinman CL, Majewski J^, Jabado N^, Lu C^. H3K27me3 spreading organizes canonical PRC1 chromatin architecture to regulate developmental programs. bioRxiv 2023 [Pubmed].

  • Li JJ, Vasciaveo A, Karagiannis D, Sun Z, Chen X, Socciarelli F, Frankenstein Z, Zou M, Pannellini T, Chen Y, Gardner K, Robinson BD, de Bono J, Abate-Shen C, Rubin MA, Loda M, Sawyers CL, Califano A, Lu C^, Shen MM^. NSD2 maintains lineage plasticity and castration-resistance in neuroendocrine prostate cancer. bioRxiv 2023 [Pubmed].

  • Zhang Y, Karagiannis D, Liu H, Lin M, Fang Y, Jiang M, Chen X, Suresh S, Huang H, She J, Shi F, Yang P, El-Rifai W, Zaika A, Oro AE, Rustgi AK, Wang TC, Lu C^, Que J^. Epigenetic regulation of p63 blocks squamous-to-neuroendocrine transdifferentiation in esophageal development and malignancy. bioRxiv 2023 [Pubmed].

Research articles & reviews

  • Karagiannis D, Wu W, Li A, Hayashi M, Chen X, Yip M, Mangipudy V, Xu X, Sánchez-Rivera FJ, Soto-Feliciano YM, Ye J, Papagiannakopoulos T, Lu C. Metabolic Reprogramming by Histone Deacetylase Inhibition Selectively Targets NRF2-activated tumors. Cell Rep 2024 [Pubmed].

  • Chen X, Li Y, Zhu F, Xu X, Estrella B, Pazos MA 2nd, McGuire JT, Karagiannis D, Sahu V, Mustafokulov M, Scuoppo C, Sánchez-Rivera FJ, Soto-Feliciano YM, Pasqualucci L, Ciccia A, Amengual JE, Lu C. Context-defined cancer co-dependency mapping identifies a functional interplay between PRC2 and MLL-MEN1 complex in lymphoma. Nat Commun 2023 [Pubmed].

  • Li Y#, Goldberg EM#, Chen X#, Xu X, McGuire JTM, Leuzzi G, Karagiannis D, Tate T, Farhangdoost N, Horth C, Dai E, Li Z, Zhang Z, Izar B, Que J, Ciccia A, Majewski J, Yoon AJ, Ailles L, Mendelsohn CL, Lu C. Histone methylation antagonism drives tumor immune evasion in squamous cell carcinomas. Mol Cell 2022 [Pubmed].

  • Sahu V, Lu C. Oncohistones: Hijacking the histone code. Annu Rev Cancer Biol 2022 [Pubmed].

  • Sheikh TN, Chen X, Xu X, McGuire JT, Ingham M, Lu C^, Schwartz GK^. Growth Inhibition and Induction of Innate Immune Signaling of Chondrosarcomas with Epigenetic Inhibitors. Mol Cancer Ther 2021 [Pubmed].

  • Weinberg DN, Rosenbaum P, Chen X, Barrows D, Horth C, Marunde MR, Popova IK, Gillespie ZB, Keogh MC, Lu C^, Majewski J^, Allis CD^. Two competing mechanisms of DNMT3A recruitment regulate the dynamics of de novo DNA methylation at PRC1-targeted CpG islands. Nat Genet 2021 53: 794-800 [Pubmed].

  • Li Y#, Chen X#, Lu C. The interplay between DNA and histone methylation: molecular mechanisms and disease implications. EMBO Rep 2021 22: e51803 [Pubmed].

  • Rajagopalan KN#, Chen X#, Weinberg DN#, Chen H, Majewski J^, Allis CD^, Lu C^. Depletion of H3K36me2 recapitulates epigenomic and phenotypic changes induced by the H3.3K36M oncohistone mutation. Proc Natl Acad Sci USA 2021 118: e2021795118 [Pubmed].

  • Weinberg DN, Papillon-Cavanagh S, Chen H, Yue Y, Chen X, Rajagopalan KN, Horth C, McGuire JT, Xu X, Nikbakht H, Lemiesz AE, Marchione DM, Marunde MR, Meiners M, Cheek M, Keogh M-C, Bareke E, Djedid A, Harutyunyan AS, Jabado N, Garcia BA, Li H, Allis CD^, Majewski J^, Lu C^. H3K36me2 recruits DNMT3A and shapes the intergenic DNA methylation landscape. Nature 2019 573: 281–286 [Pubmed]

    - Featured in Cancer Discovery; See here for a video summary

 

2010-2017

  • Papillon-Cavanagh S#, Lu C#, Gayden T, Mikael LG, Bechet D, Karamboulas C, Ailles L, Karamchandani J, Weinreb I, Goldstein D, Lewis PW, Dancu O, Dhaliwal S, Stecho W, Howlett CJ, Mymryk JS, Barrett JW, Nichols AC, Allis CD, Majewski J, Jabado N. Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomas. Nat Genet 2017 49: 180-185 [Pubmed].

- Featured in Radio Canada International

  • Weinberg DN, Allis CD^, Lu C^.  Oncogenic mechanisms of histone H3 mutations. Cold Spring Harb Perspect Med 2017 7: pii: a026443 [Pubmed].

  • Bayliss J#, Mukherjee P#, Lu C#, Jain SU, Chung C, Martinez D, Sabari B, Margol AS, Panwalkar P, Parolia A, Pekmezci M, McEachin RC, Cieslik M, Tamrazi B, Garcia BA, La Rocca G, Santi M, Lewis PW, Melnik A, Allis CD, Thompson CB, Chinnaiyan AM, Judkins AR, Venneti S.  Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas. Sci Transl Med 2016 8: 366ra161 [Pubmed].

-Highlighted in Cancer Research and Neurosurgery

  • Lu C, Jain SU, Hoelper D, Bechet D, Molden RC, Ran L, Murphy D, Venneti S, Hameed M, Pawel BR, Wunder J, Dickson BC, Lundgren SM, Jani KS, De Jay N, Papillon-Cavanagh S, Andrulis IL, Sawyer SL, Grynspan D, Turcotte RE, Nadaf J, Fahiminiyah S, Muir TW, Majewski J, Thompson CB, Chi P, Garcia BA, Allis CD, Jabado N, Lewis PW. Histone H3K36 mutations promote sarcomagenesis through altered histone methylation landscape. Science 2016 352: 844-9 [Pubmed].

- Highlighted in Nat Rev Cancer, Nat Rev Genetics, Cancer Discov

  • Lu C, Venneti S, Akalin A, Fang F, Ward PS, Dematteo RG, Intlekofer AM, Chen C, Ye J, Hameed M, Nafa K, Agaram NP, Cross JR, Khanin R, Mason CE, Healey JH, Lowe SW, Schwartz GK, Melnick A, Thompson CB. Induction of sarcomas by mutant IDH2. Genes Dev 2013 27: 1986-98 [Pubmed].

- Highlighted in Nat Rev Cancer

  • Lu C, Thompson CB. Metabolic regulation of epigenetics. Cell Metab 2012 16: 9-17 [Pubmed].

  • Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, Edwards CR, Khanin R, Figueroa ME, Melnick A, Wellen KE, O'Rourke DM, Berger SL, Chan TA, Levine RL, Mellinghoff IK, Thompson CB. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012 483: 474–78 [Pubmed]. 

- Highlighted in Nature News, Cell Res, Sci Signal, Nat Rev Cancer and Cancer Res

  • Figueroa ME#, Abdel-Wahab O#, Lu C#, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, Peeters JK, Liu W, Choe SE, Fantin VR, Paietta E, Löwenberg B, Licht JD, Godley LA, Delwel R, Valk PJ, Thompson CB, Levine RL, Melnick A. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010 18: 553-67 [Pubmed].